Search Results - "Golm, G. T."

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis by Engel, S S, Williams-Herman, D E, Golm, G T, Clay, R J, Machotka, S V, Kaufman, K D, Goldstein, B J

“…Recent case reports of acute pancreatitis in patients with type 2 diabetes (T2DM) treated with incretin-based therapies have triggered interest regarding the…”
Get more information

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes by Yoon, K H, Shockey, G R, Teng, R, Golm, G T, Thakkar, P R, Meehan, A G, Williams-Herman, D E, Kaufman, K D, Amatruda, J M, Steinberg, H

“…To assess the safety and efficacy of initial combination therapy with sitagliptin and pioglitazone compared with pioglitazone monotherapy in drug-naïve…”
Get more information

Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP–IPV–PRP∼T–HBs) combination vaccine by Stojanov, S, Liese, J.G, Belohradsky, B.H, Vandermeulen, C, Hoppenbrouwers, K, Van der Wielen, M, Van Damme, P, Georges, B, Dupuy, M, Scemama, M, Watson, M, Fiquet, A, Stek, J.E, Golm, G.T, Schödel, F.P, Kuter, B.J

“…Abstract Background Administration of two doses of hepatitis A (HA) vaccine to children ≥2 years of age has been shown to be protective. The present study…”
Get full text

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone-a factorial study by Henry, R. R., Staels, B., Fonseca, V. A., Chou, M. Z., Teng, R., Golm, G. T., Langdon, R. B., Kaufman, K. D., Steinberg, H., Goldstein, B. J.

“…Aim To evaluate the efficacy and safety of initial combination therapy of sitagliptin 100 mg/day coadministered with all marketed doses of pioglitazone in…”
Get full text

A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus by Shankar, R R, Xu, L, Golm, G T, O'Neill, E A, Goldstein, B J, Kaufman, K D, Engel, S S

“…In the USA, 45% of patients with type 2 diabetes mellitus (T2DM) are elderly (≥ 65 years old). In general, use of sulfonylurea increases with patient age as…”
Get more information

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes by Wainstein, J., Katz, L., Engel, S. S., Xu, L., Golm, G. T., Hussain, S., O'Neill, E. A., Kaufman, K. D., Goldstein, B. J.

“…Aims: To evaluate the efficacy and safety of initial therapy with a fixed‐dose combination (FDC) of sitagliptin and metformin compared with pioglitazone in…”
Get full text

Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes by Williams-Herman, D., Xu, L., Teng, R., Golm, G. T., Johnson, J., Davies, M. J., Kaufman, K. D., Goldstein, B. J.

“…Aim: To examine the effect of sitagliptin and metformin, alone and in combination, on modelled parameters of β‐cell function in patients with type 2 diabetes…”
Get full text

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study by Yoon, K. H., Steinberg, H., Teng, R., Golm, G. T., Lee, M., O'Neill, E. A., Kaufman, K. D., Goldstein, B. J.

“…Aim: To assess the 54‐week efficacy of initial combination therapy with sitagliptin and pioglitazone, compared with pioglitazone monotherapy, and to assess…”
Get full text

Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes by Katzeff, H.L., Williams-Herman, D., Xu, L., Golm, G.T., Wang, H., Dong, Q., Johnson, J.R., O'Neill, E.A., Kaufman, K.D., Engel, S.S., Goldstein, B.J.

“…Abstract Objective: To evaluate the efficacy of once daily sitagliptin 100 mg as monotherapy or as add-on to metformin in patients with type 2 diabetes…”
Get full text

Primary Objective of Study of Sitagliptin in Patients With ESRD on Dialysis by Arjona Ferreira, J.C., MD, Golm, G.T., PhD, Goldstein, B.J., MD, PhD

Get full text

Semi-parametric models for mismeasured exposure information in vaccine trials by Golm, Gregory T., Halloran, M. Elizabeth, Longini Jr, Ira M.

“…Exposure to infection information is important for estimating vaccine efficacy, but it is difficult to collect and inherently prone to missingness and…”
Get full text

Semiparametric Methods for Multiple Exposure Mismeasurement and a Bivariate Outcome in HIV Vaccine Trials by Golm, Gregory T., Elizabeth Halloran, M., Longini Jr, Ira M.

“…Exposure to infection information is important for estimating vaccine efficacy, but it is difficult to collect and prone to missingness and mismeasurement. We…”
Get full text

Life expectancy in a Tulsa cemetery: growth and population structure of the lichen Xanthoparmelia cumberlandia by Golm, G.T. (University of Tulsa, Tulsa, OK), Hill, P.S, Wells, H

“…The demographics of a population of the foliose lichen Xanthoparmelia cumberlandia growing on gravestones in a Tulsa cemetery are presented. Because of the…”
Get full text